ENDRA Life Sciences reports Q1 net loss of $2.8M; advances TAEUS liver system with FDA and UK clinical study

ENDRA Life Sciences Inc.

Net loss of $2.8M ($0.26 per share) vs $2.9M ($0.93 per share) in Q1 2023; operating expenses $2.8M.
Cash and cash equivalents were $1.1M as of March 31, 2024.
First TAEUS system installed at King's College Hospital (UK) for a clinical study evaluating liver fat vs MRI (approx 75 subjects).
FDA pre-submission meeting scheduled in Q2 2024 to align on clinical requirements for De Novo application.
Expanded IP portfolio to 80 issued patents globally; exploring licensing for non-core indications.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported the three months ended March 31, 2024 results: net income $2.8 million, or $0.26 per share, EPS $0.26 per share.

Period: the three months ended March 31, 2024
Net income: $2.8 million, or $0.26 per share
EPS: $0.26 per share
Result: reported results

Exact text from the filing

Net loss in the first quarter of 2024 was $2.8 million, or $0.26 per share, compared with a net loss of $2.9 million, or $0.93 per share, in the first quarter of 2023.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-006233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.